Media Release
- Latest from daratumumab Phase I/II study in relapsed/refractory multiple myeloma
- Pre-clinical data from HuMax-TF-ADC program
- Abstracts available online at ASCO website
Copenhagen, Denmark; May 16, 2013 – Genmab A/S (OMX: GEN) announced today that the latest data from the ongoing Phase I/II study of daratumumab in relapsed/refractory multiple myeloma will be presented in an oral session in the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 31-June 4. Daratumumab is being developed under a collaboration with Janssen Biotech, Inc. and was recently granted Breakthrough Therapy Designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD. Data from two other Genmab programs will also be presented. Abstracts have been published at the ASCO website at http://abstracts2.asco.org/.
Abstracts
Daratumumab, a CD38 safety study in MM – Open-label, dose escalation followed by open-label extension single-arm study – Abstract # 8512 Oral presentation June 3 between 8:00-11:00AM Central Time (CT)
An antibody-drug conjugate targeting tissue factor induces tumor regression in xenograft models with heterogeneous target expression – Abstract # 3066 Poster presentation June 3 at 8:00-11:45AM CT
An open-label single-arm, Ph II trial of zalutumumab, a human anti-EGFR mAb, in patients with non-curable SCCHN who have failed standard platinum-based chemotherapy – Abstract # 6065 Poster presentation June 1 at 8:00-11:45AM CT
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; the DuoBody™ logo; HuMax®; HuMax-CD20®; DuoBody®, HexaBody™ and UniBody®. Arzerra® is a trademark of GlaxoSmithKline.
Media Release no. 02
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
